Last A$0.02 AUD
Change Today 0.00 / 0.00%
Volume 0.0
As of 12:24 AM 08/8/14 All times are local (Market data is delayed by at least 15 minutes).

actinogen ltd (ACW) Snapshot

Open
A$0.02
Previous Close
A$0.02
Day High
A$0.02
Day Low
A$0.02
52 Week High
03/24/14 - A$0.05
52 Week Low
09/17/13 - A$0.01
Market Cap
3.6M
Average Volume 10 Days
600.0
EPS TTM
A$-0.0038
Shares Outstanding
202.6M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for ACTINOGEN LTD (ACW)

Related News

No related news articles were found.

actinogen ltd (ACW) Related Businessweek News

No Related Businessweek News Found

actinogen ltd (ACW) Details

Actinogen Limited discovers and isolates environmental bacteria known as the actinomycetes that are found in Western Australia. It primarily develops actinomycetes that produce plant growth hormones; bacteria killing actinomycetes, which can be used to produce antibiotics; and salt tolerant actinomycetes used to grow plants and crops in salt affected environments. The company was formerly known as Australian Biogen Limited and changed its name to Actinogen Limited in August 2007. Actinogen Limited is based in West Perth, Australia.

actinogen ltd (ACW) Top Compensated Officers

Executive Chairman
Total Annual Compensation: A$39.4K
Co-Founder and Scientific Consultant
Total Annual Compensation: --
Chief Financial Officer
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

actinogen ltd (ACW) Key Developments

Actinogen Limited. Appoints Brendan De Kauwe as Executive Chairman

The Board of Actinogen Limited announced that the company's Executive Director, Dr. Brendan de Kauwe, has been appointed as Executive Chairman.

Actinogen Limited Reports Earnings Results for the Half Year Ended December 31, 2013

Actinogen Limited reported earnings results for the half year ended December 31, 2013. For the period, the company’s revenue from continuing operations was AUD 20,000. Loss before income tax was AUD 153,242 compared to AUD 17,908 a year ago. Loss for the period was AUD 153,242 compared to AUD 17,908 a year ago. Diluted loss per share attributable to the ordinary equity holders of the company was 0.15 cents compared to 0.02 cents a year ago. Net cash outflow from operating activities was AUD 119,735 compared to net cash inflow from operating activities of AUD 51,788 a year ago. Purchase of property, plant and equipment was AUD 5,252.

Leaf Energy Signs Collaboration Agreement with Actinogen Ltd on Certain Bacterial Strains from the Actinomycetes Family

Leaf Energy Ltd. has signed an agreement with Actinogen Ltd. to collaborate on certain bacterial strains from the Actinomycetes family that are relevant to Leaf Energy's Glycerol Pretreatment Process. Leaf Energy is interested in these Actinomycetes strains as it believes that they have the potential to add value to Leaf Energy's Glycerol Pretreatment process in two ways: Firstly, the Actinomycetes strains grow on glycerol as a feedstock. Secondly they have been shown to produce enzymes (Cellulases and Lignases) that may be useful in the Glycerol Pretreatment Process or generate valuable products (e.g. Shikimic Acid) that can add to the economics of the process. Under the terms of the agreement Leaf Energy will spend up to $100,000 (minimum $20,000) on progressing the work already undertaken by Actinogen. Once the preliminary work is done, and if the research has progressed to Leaf Energy's satisfaction, then Leaf Energy has an option to continue the work in ways that will benefit its process and objectives. If the trials are successful (as determined by Leaf Energy) then Leaf Energy can request an exclusive license to the background IP and the IP developed through the collaboration in return for a royalty on profits. Actinogen has progressed work on the three strains and/or areas of interest to different levels: the Actinomycetes strain that produces cellulases has been tested externally by the CSIRO at a 10 litre volume with encouraging results. Work on the production of Lignases and Shikimic acid is at a very early stage having only been progressed in the laboratory at a molecular level.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACW:AU A$0.02 AUD 0.00

ACW Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for ACW.
View Industry Companies
 

Industry Analysis

ACW

Industry Average

Valuation ACW Industry Range
Price/Earnings NM Not Meaningful
Price/Sales NM Not Meaningful
Price/Book 2.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACTINOGEN LTD, please visit www.actinogen.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.